COX-2s pending approval may also carry heart risks

The FDA suggested two COX-2 drugs pending approval, Merck's Arcoxia and Novartis' Prexige, carry similar cardiovascular risks to Merck's Vioxx.
The FDA raised questions about the drugs in staff documents posted ahead of this week's joint-session on COX-2s to examine their risks and benefits.
The FDA said in the documents that there was an increase in the number of cardiovascular events and hypertension in people using Arcoxia.
The documents also said a study involving patients taking Prexige and patients taking naproxen showed there was an increase in the number of cardiac deaths and non-fatal heart attacks and strokes among those taking Prexige.
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.